Guselkumab, an anti-interleukin-23p19 monoclonal antibody, modulates core psoriatic arthritis gene expression in two phase III clinical trials (DISCOVER-1 and DISCOVER-2)
BRITISH JOURNAL OF DERMATOLOGY（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined